Актинический кератоз

1. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol
2000; 42 (1 Pt 2): 23–4
2. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses
to squamous cell carcinoma. Lancet 1988; 1 (8589): 795–7.
3. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994;
131 (4): 455–64.
4. O’Beirn SFO, Judge P, Maccon CF, Martin CF. Skin cancer in County Galway,
Ireland. In: Proceedings of the Sixth National Cancer Conference, sponsored by
the American Cancer Society Inc. and the National Cancer Institute, September
1968. Philadelphia: Lippincott, 1970; p. 489–500.
5. Harvey I, Frankel S, Marks R et al. Non-melanoma skin cancer and solar
keratoses. 1. Methods and descriptive results of the South Wales skin cancer study.
Br J Cancer 1996; 74: 1302–7.
6. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar
damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000;
142: 1154–9.
7. Ishioka P, Marques SA, Hirai AT et al. Prevalence of precancerous skin lesions
and non-melanoma skin cancer in Japanese-Brazilians in Bauru, São Paulo State,
Brazil. Cad Saude Publica 2009; 25 (5): 965–71.
8. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma.
J Am Acad Dermatol 2000; 42: 4–7.
9. Frost CA, Green AC, Williams GM. The prevalence and determinants of
solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol
1998; 139 (6): 1033–9.
10. Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol
2006; 55 (5): 741–60; quiz 761–4.
11. Barnaby JW, Styles AR, Cockerell CJ. Actinic keratoses. Differential diagnosis
and treatment. Drugs Aging 1997; 11: 186–205.
12. Lang PG Jr. Management of Actinic keratosis. Compr Ther 2003; 29: 108–14.
13. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic
keratosis into invasive squamous cell carcinoma: evidence and evolving classification
schemes. Clin Dermatol 2004; 22: 189–96.
14. Weissenborn SJ, Nindl I, Purdie K et al. Human Papillomavirus-DNA Loads
in Actinic Keratoses Exceed those in Non-Melanoma Skin Cancers. J Invest Dermatol
2005; 125: 93–7.
15. McBride P, Neale R, Pandeya N, Green A. Sun-related factors, betapapillomavirus,
and actinic keratoses: a prospective study. Arch Dermatol 2007; 143
(7): 862–8.
16. Alam M. Actinic keratoses: prevalence, pathogenesis, presentation and prevention,
Adv Stud Med 2006, 6 (8A): S785–90.
17. Lober BA, Lober CW. Actinic keratosis is squamous cell carcinoma. South
Med J 2000; 93: 650–5.
18. Lever's Histopathology of the Skin. 9th ed. Philadelphia, PA: Lippincott
Williams and Wilkins, 2005.
19. Shai A, Halevy S, Grunwald MH et al. Transition between solar keratosis
and basal cell carcinoma. Eur J Dermatol 1999; 9 (1): 35–8.
20. Пальцев М.А., Потекаев Н.Н., Казанцева И.А. и др. Клинико-
морфологическая диагностика заболеваний кожи. М.: Медицина, 2005.
21. Uhlenhake EE, Sangueza OP, Lee AD, Jorizzo JL. Spreading pigmented
actinic keratosis: A review. J Am Acad Dermatol 2010.
22. Goldberg LH, Joseph AK, Tschen JA. Proliferative actinic keratosis. Int J
Dermatol 33 (5): 341–5.
23. Mauriello JAJr, Napolitano J, McLean I. Actinic keratosis and dysplasia of
conjunctiva: a clinicopathologic study of 45 cases. Can J Ophtalm 1995; 30: 312–6.
24. Montagna W, Kirchner S, Carlisle K. Histology of sun-damaged human
skin. J Am Acad Dermatol 1989; 21: 907–18.
25. Mitchell RE. Chronic solar elastosis: an electron microscopic study of the
dermis. J Invest Dermatol 1967; 48: 203–20.
26. Dinehart S. The treatment of actinic keratoses. J Am Acad Dermatol 2000;
42: 25–8.
27. Thai K-E, Fergin P, Freeman M et al. A prospective study of the use of
cryosurgery for the treatment of actinic keratoses. Int J Derm 2004; 43 (9): 687–92.
28. Feldman SR, Fleischer AB, Williford PM, Jorrizzo JL. Destructive procedures
are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol
1999; 40: 43–7.
29. Wollina U, Konrad H, Karamfilov T. Treatment of common warts and
actinic keratoses by Er: YAG laser. J Cutan Laser Ther 2001; 3: 63–6.
30. Yu TC, Rahman Z, Ross BS. Actinic keratoses-surgical and physical therapeutic
modalities. Cutis 2003; 71: 381–4.
31. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: Mechanism of Action
in Human Skin and Actinic. Keratoses, Arch Derm 1970; 101: 132–9.
32. Jorizzo J, Stewart D, Bucko A et al. Randomized trial evaluating a new 0,5%
fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment
in patients with actinic keratosis. Cutis 2002; 10: 335–9.
33. Levy S, Furst K, Chern W. A comparison of the skin permeation of three
topical 0,5% fluorouracil formulations with that of a 5% formulation. Clin Ther
2001; 23: 901–7.
34. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability
of 0,5% fluorouracil cream and 5% fluorouracil cream applied to each side of
the face in patients with actinic keratosis. Clin Ther 2002; 24 (6): 990–1000.
35. Gupta AK. The management of actinic keratoses in the United States with
topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002; 70: 30–6.
36. Sachsenberg-Studer EM. Tolerance of topical retinaldehyde in humans.
Dermatology 1999; 199: S61–3.
37. Sorg O, Tran C, Saurat JH. Cutaneous vitamins A and E in the context of
ultraviolet- or chemically-induced oxidative stress. Skin Pharmacol Appl Skin
Physiol 2001; 14: 363–72.
38. Kligman AL, Thorne EG. Topical therapy of actinic keratoses with tretinoin.
In: Marks R, editor. Retinoids in cutaneous malignancy. Oxford, UK: Blackwell
Scientific Publications 1991; p. 66–73.
39. Thorne EG. Long-term clinical experience with a topical retinoid. Br J Dermatol
1993; 127 (Suppl.): 31–6.
40. Campanelli A, Naldi L. A retrospective study of the effect of long-term
topical application of retinaldehide (0,05%) on the development of actinic keratosis.
Dermatology 2000; 205: 146–52.
41. Kang S, Goldfab MT, Weiss JS et al. Assesment of adapalene gel for the
treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol
2003; 49: 83–90.
42. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of
cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med
1997; 216: 201–10.
43. Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor
activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–11.
44. Nelson C, Rigel D, Smoth S et al. Phase IV, open label assessment of the
treatment of actinic keratosis with 3% diclofenac sodium topical gel (Solaraze).
J Drugs Dermatol 2004; 3: 401–7.
45. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate
immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol
2002; 3: 196–200.
46. Miller RL, Gerster JF, Owens ML et al. Imiquimod applied topically: a novel
immune response modifier and new class of drug. Int J Immunopharmacol 1999;
21: 1–14.
47. Stockfleth E, Meyer T, Benninghoff B et al. A randomized, double-blind,
vehicle-controlled study to assess 5 imiquimod cream for the treatment of multiple
actinic keratoses. Arch Dermatol 2002; 138: 1498–502.
48. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new
actinic keratoses after topical 5% imiquimod cream treatment: a long-term followup
study. Arch Dermatol 2004; 140: 1542.
49. Szeimies RM, Karrer S, Radakovic-Fijan S et al. Photodynamic therapy
using topical methyl 5-aminolevulinate compared with cryotherapy for actinic
keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258–62.
50. Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic
therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy
in patients with actinic keratosis: a prospective, randomized study. Dermatol
Treat 2003; 14: 99–106.
51. Pariser DM, Lowe NJ, Stewart DM et al. Photodynamic therapy with
topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized
multicenter trial. J Am Acad Dermatol 2003; 48: 227–32.
52. Солнцезащитные экраны. Европейское руководство по лечению
дерматологических болезней. Под ред. А.Д.Кацамбаса, Т.М.Лотти. М.:
Медпресс-информ, 2008.

А.Н.Хлебникова1, Е.В.Селезнева2
1. Первый МГМУ им. И.М.Сеченова;
2. ООО «Оксигон», Москва